Search details
1.
Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
Int J Mol Sci
; 25(9)2024 Apr 24.
Article
in English
| MEDLINE | ID: mdl-38731844
2.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37355448
3.
Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy.
Cytometry A
; 101(7): 597-605, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35507402
4.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30796151
5.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
BJU Int
; 123(1): 98-105, 2019 01.
Article
in English
| MEDLINE | ID: mdl-29956884
6.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Anticancer Drugs
; 29(7): 705-709, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29846246
7.
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Future Oncol
; 14(26): 2691-2699, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30207488
8.
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.
Oncology
; 92(5): 269-275, 2017.
Article
in English
| MEDLINE | ID: mdl-28208153
9.
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
J Urol
; 193(6): 1905-10, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25433306
10.
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
Future Oncol
; 11(23): 3159-66, 2015.
Article
in English
| MEDLINE | ID: mdl-26544922
11.
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Future Oncol
; 10(10): 1741-50, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24641206
12.
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
Cancer Treat Rev
; 126: 102723, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38555857
13.
Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.
Case Rep Oncol
; 17(1): 564-572, 2024.
Article
in English
| MEDLINE | ID: mdl-38645572
14.
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.
Future Oncol
; 9(6): 831-43, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23718304
15.
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Cancer Treat Rev
; 115: 102525, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36822009
16.
Immunotherapy in urothelial cancer: current status and future directions.
Expert Rev Anticancer Ther
; 23(11): 1141-1155, 2023.
Article
in English
| MEDLINE | ID: mdl-37772970
17.
De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
Cancers (Basel)
; 15(20)2023 Oct 11.
Article
in English
| MEDLINE | ID: mdl-37894312
18.
Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.
Cancers (Basel)
; 15(5)2023 Feb 28.
Article
in English
| MEDLINE | ID: mdl-36900309
19.
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
Front Oncol
; 13: 1232476, 2023.
Article
in English
| MEDLINE | ID: mdl-37609387
20.
Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers.
Biology (Basel)
; 12(6)2023 Jun 17.
Article
in English
| MEDLINE | ID: mdl-37372161